Cover Image

OP 6.5 - 00164 Nanobody-engineered AAV vectors for CD4-targeted gene therapy

Saved in:

Bibliographic Details
Main Authors:	U. Lange (Author), M. Hamann (Author), D. Foth (Author), P. Kumar (Author), U.C. Lange (Author)
Format:	Book
Published:	Elsevier, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Rapamycin immune tolerization enables gene transfer following subcutaneous delivery of AAV6 but not CD4-retargeted AAV6 vectors in AAV-seropositive rhesus macaques
by: K. Jerome, et al.
Published: (2019)

Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs
by: Carolina Pinto-Espinoza, et al.
Published: (2022)

AAV gene therapy vectors in the TMJ
by: Sabine M. Brouxhon, et al.
Published: (2022)

CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector
by: Giridhar Murlidharan, et al.
Published: (2016)

OP 6.8 - 00102 In vivo evolution of env in SHIV-AD8-infected rhesus macaques after AAV-eCD4-Ig therapy
by: D. O'Hagan, et al.
Published: (2022)

Enhanced Transduction of Human Hematopoietic Stem Cells by AAV6 Vectors: Implications in Gene Therapy and Genome Editing
by: Hua Yang, et al.
Published: (2020)

Lactobacilli as a Vector for Delivery of Nanobodies against Norovirus Infection
by: Yoshikazu Yuki, et al.
Published: (2022)

OP 6.1 It's a mountain not a hill: Progress made in realizing AAV-delivered inhibitors for an HIV cure
by: Matthew R. Gardner
Published: (2022)

Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy
by: Arun Srivastava
Published: (2023)

Immune responses to AAV vectors, from bench to bedside
by: Hildegard Buning
Published: (2015)

Nanobody
Published: (2021)

Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer
by: Ruchita Selot, et al.
Published: (2017)

Controlled Release of rAAV Vectors from APMA-Functionalized Contact Lenses for Corneal Gene Therapy
by: Fernando Alvarez-Rivera, et al.
Published: (2020)

AAV-vectored base editor trans-splicing delivers dystrophin repair
by: Zhen Li, et al.
Published: (2023)

Engineered AAV2.7m8 Serotype Shows Significantly Higher Transduction Efficiency of ARPE-19 and HEK293 Cell Lines Compared to AAV5, AAV8 and AAV9 Serotypes
by: Dzerassa Gurtsieva, et al.
Published: (2024)

Tissue-Dependent Expression and Translation of Circular RNAs with Recombinant AAV Vectors In Vivo
by: Rita M. Meganck, et al.
Published: (2018)

AAV-based gene replacement: The promise of gene therapy for deafness
by: Jieyu Qi, et al.
Published: (2024)

OP 6.3 - 00150 Delivery and long-term expression of CCR5-blocking monoclonal antibody Leronlimab with AAV for ART-free remission from SHIV viremia
by: G. Webb, et al.
Published: (2022)

How long is long-term? Delivery of anti-HIV antibodies using AAV vector
by: J. Martinez-Navio, et al.
Published: (2019)

Replacing daily cART with AAV-expressed eCD4-Ig
by: M. Gardner, et al.
Published: (2019)

Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
by: Nicholas M. Kanaan, et al.
Published: (2017)

2 Generation of new model systems for HIV infection to explore epigenetic effects of HIV integration site choice
by: J.K. Bialek, et al.
Published: (2017)

Subgenomic particles in rAAV vectors result from DNA lesion/break and non-homologous end joining of vector genomes
by: Junping Zhang, et al.
Published: (2022)

BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
by: Vanessa Strings-Ufombah, et al.
Published: (2021)

An AAV-Based NF-κB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases
by: Luo T, et al.
Published: (2022)

OP 6.2 - 00195 Targeted genome engineering of human t cells in vivo for HIV cure
by: P. Kumar, et al.
Published: (2022)

Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models
by: Jonatan Dewulf, et al.
Published: (2023)

Agonistic nanobodies and antibodies to human VISTA
by: Yu-Heng Vivian Ma, et al.
Published: (2021)

Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift
by: Adrien Laroche, et al.
Published: (2022)

Advanced Characterization of DNA Molecules in rAAV Vector Preparations by Single-stranded Virus Next-generation Sequencing
by: Emilie Lecomte, et al.
Published: (2015)

Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variants
by: Ella Borgenheimer, et al.
Published: (2024)

Enhanced transgene expression from single-stranded AAV vectors in human cells in vitro and in murine hepatocytes in vivo
by: Yuan Lu, et al.
Published: (2024)

Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity
by: Fuhua Wu, et al.
Published: (2023)

An efficient AAV vector system of Rec2 serotype for intravenous injection to study metabolism in brown adipocytes in vivo
by: Janina Behrens, et al.
Published: (2024)

Targeted Transgene Activation in the Brain Tissue by Systemic Delivery of Engineered AAV1 Expressing CRISPRa
by: Cia-Hin Lau, et al.
Published: (2019)

Nanobody-based CAR-T cells for cancer immunotherapy
by: Pouya Safarzadeh Kozani, et al.
Published: (2022)

Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery
by: Beggah Ahmed T, et al.
Published: (2009)

Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy
by: Anne Louise Askou, et al.
Published: (2019)

PP 8.5 - 00080 Fc-engineering of anti-HIV-1 antibodies and nanobodies to improve Fc mediated effector functions
by: A. Schriek, et al.
Published: (2022)

Affinity is an important determinant of the anti-trypanosome activity of nanobodies.
by: Guy Caljon, et al.
Published: (2012)